167 related articles for article (PubMed ID: 24875798)
21. p16, HPV, and Cetuximab: What Is the Evidence?
Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB
Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718
[TBL] [Abstract][Full Text] [Related]
22. Afatinib in squamous cell carcinoma of the head and neck.
Specenier P; Vermorken J
Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
[TBL] [Abstract][Full Text] [Related]
23. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas.
Duray A; Descamps G; Decaestecker C; Sirtaine N; Gilles A; Khalifé M; Chantrain G; Depuydt CE; Delvenne P; Saussez S
Oncol Rep; 2013 Jul; 30(1):371-6. PubMed ID: 23603900
[TBL] [Abstract][Full Text] [Related]
25. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
27. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy.
de Andrade DA; Machiels JP
Curr Opin Oncol; 2012 May; 24(3):211-7. PubMed ID: 22498572
[TBL] [Abstract][Full Text] [Related]
28. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
Nakano K; Marshall S; Taira S; Sato Y; Tomomatsu J; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Kawabata K; Takahashi S
Oral Oncol; 2017 Oct; 73():21-26. PubMed ID: 28939072
[TBL] [Abstract][Full Text] [Related]
29. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
30. Immune biomarkers of anti-EGFR monoclonal antibody therapy.
Trivedi S; Concha-Benavente F; Srivastava RM; Jie HB; Gibson SP; Schmitt NC; Ferris RL
Ann Oncol; 2015 Jan; 26(1):40-47. PubMed ID: 24997207
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis.
De Felice F; Bossi P
Oral Oncol; 2023 Feb; 137():106275. PubMed ID: 36542994
[No Abstract] [Full Text] [Related]
33. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
Li JZ; Zheng JW; Zhang ZY
Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
Massa E; Dessì M; Gaspardini G; Saba F; Cherchi V; Mantovani G
Oral Oncol; 2010 Nov; 46(11):818-21. PubMed ID: 20920877
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2011 Apr; 11(4):511-24. PubMed ID: 21504318
[TBL] [Abstract][Full Text] [Related]
36. HPV-related Oropharyngeal Carcinoma: A Review of Clinical and Pathologic Features With Emphasis on Updates in Clinical and Pathologic Staging.
Buckley L; Jackett L; Clark J; Gupta R
Adv Anat Pathol; 2018 May; 25(3):180-188. PubMed ID: 29394171
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.
Chang PM; Hsieh YY; Chen MH; Tzeng CH; Chu PY; Chang SY; Chen PM; Yang MH
J Chin Med Assoc; 2010 Jun; 73(6):292-9. PubMed ID: 20603086
[TBL] [Abstract][Full Text] [Related]
38. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.
Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P
Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ;
Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab Doubles Survival for Patients with HNSCC.
Cancer Discov; 2016 Jul; 6(7):OF3. PubMed ID: 27217382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]